AbbVie Already Dividend King? Why Apogee Deal Could Cement a Dynasty
AbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Why Do Active Funds Underperform Benchmark? This overview breaks down fees, manager skill, and market efficiency to explain gaps in performance and how to navigate them.
22,441 articlesAbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Meta unveils a sweeping 5-GW AI data center expansion in rural Louisiana, widening a rift over economic benefits and ...
When a chief executive sells stock, investors ask if the move is a red flag or a routine tax-related step. This piece...
Both Tesla and Rivian have slipped about 12% this year. This article cuts through the market noise to evaluate fundam...
WD-40 has evolved from a single iconic spray into a disciplined maintenance-products company. This deep dive explains...
How do two AI infrastructure players compare when it comes to revenue scale? This article breaks down the factors, me...
On July 22, AI-driven hardware names moved the dial as SMCI posted a surprising margin beat and a burst of orders. Th...
New reports say Lagarde is weighing an earlier departure, which could derail the ECB's digital euro plan and MiCA rol...
Caterpillar—a 100-year-old icon in heavy equipment—is redefining its path by embracing AI-enabled infrastructure, dat...
As Omnicom wraps up the 2025 fiscal year, investors want clarity on growth, margins, and capital allocation. This gui...
November 2025 marks a new milestone as the Bitcoin Lightning Network surpasses $1B in monthly volume, signaling a shi...
When a beloved tech stock slips after earnings, investors ask one question: should stock? This guide breaks down how ...